Reig jofré ends 2011 with a turnover of EUR 110 million and 53% in volume of international business

the international presence of the group reaches the 50 countries thanks to the signing of an agreement of distribution in Hong Kong

-El group, international leader in manufacture of derivative of penicillin antibiotics and injectable pharmaceuticals lyophilization, opens sales office in United Kingdom after winning a contract to supply a gastric protector in hospitals in the regions of Central and South-East of England.

-fruit of the acquisition of Sweden, Reig Jofré Bioglan has carried out trials of clinical efficacy between Spain and Sweden for the development and global introduction, in the medium term, a product which acts within the respiratory, preventing allergic reactions

Barcelona, April 2012.- group Reig Jofré, one of the leading global manufacturers of injectable pharmaceutical specialties, both liofilizadas as antibiotics derived from penicillin, reinforces its strategy of internationalization to be present in 50 countries with the distribution of its productsmanufactured in Spain. This has been possible thanks to the signing of a distribution agreement in Hong Kong of antibiotics for infections in the hospital setting, manufactured at its plant in Toledo.

The group closes 2011 with a turnover of EUR 110 million and 53% in volume of international business and opens sales office in United Kingdom, after winning a contract for the supply of a gastric protector injectable in the regions of Central and South-East of England hospitals during an initial period of two years. This is the first of an extensive portfolio of products which will be marketed and distributed in the United Kingdom under the brand name room (which specializes in injectable hospital).

With more than 145 customers worldwide, currently Reig Jofré is in negotiations for its introduction in the market of Czech Republic, Hungary, Norway, Korea, Japan, Pakistan, Egypt and Algeria. The Group also participates in the global STOP TB programme, supplying antibiotics of first line of treatment to the World Health Organization (WHO) and UNDP of United Nations in its fight to combat tuberculosis worldwide.

Between Spain and Sweden clinical efficacy trials

Result of the acquisition in 2009 of Bioglan AB in Sweden Рwith the contribution of a team of r & d in the areas of Dermatology, respiratory, as well as a plant specializing in dermatological products topics-Reig Jofr̩ has conducted joint trials of clinical efficacy between Spain and Sweden.

Result of such tests, carried out with the collaboration of Swedish scientists, is possible the development and marketing, in the medium term, of a product which acts within the respiratory, preventing allergic reactions, through the mucosa.

The acquisition of the business unit of Malmö was the real internationalization of the laboratory and its entry into a market so advanced in knowledge and technology as the Norse. In that regard, it has allowed to directly reach their markets, through the own developed in Spain product marketing, and has made possible the identification of research projects, both in the Nordic markets and in other countries. All this has enabled access and contact with important research centres located in the médico-tecnológico cluster situated in the South of Sweden, known as Medicon Valley, whose r & d team has collaborated with Reig Jofré Spain for the development of this new product that acts on the nasal mucosa to prevent allergy.

Reig Jofré Group

Reig Jofré group is a company founded in 1929 in Barcelona, from family and national capital and strong growth in recent years. It is structured around three divisions: a division of r & d and records with extensive experience in pharmaceutical at European level regulation and strong commitment to research with a comprehensive projects and qualification portfolio good ” in Group A of the Plan Profarma. A Pharma division dedicated to the marketing of own pharmaceutical specialties under the Reig Jofré, Medea, Medea antibiotics, Orravan and room brands in the areas of Dermatology, respiratory, paediatrics, antibiotics and Gynecology, with three commercial networks at the national level, a medical visitand, pharmacies and the third to hospitals. Its specialities include: Ardine, Ardineclav, budesonide Easyhaler, Anaclosil, Prepar, Otocerum, Complidermol, or Pulmictán. The third Division, structured around the industrial area, is leader in the specialized manufacture of lyophilized sterile, both chemical and biotechnological products, and antibiotics penicilánicos, as well as in the development, manufacture and out-licensing of dossiers of pharmaceutical products worldwide. Manufacturing is carried out on the soles of RJ Toledo (antibiotics penicilánicos), RJ Sant Joan Despí (Liofilizados). Since 2009 RJ Group acquired Bioglan AB Sweden, giving the group a team of r & d in the area of Dermatology, as well as the ability to reach commercially with own products to the Nordic countries and the specialized manufacture of products for topical use. It has a portfolio of clients of 160 laboratories worldwide, with a volume of manufacture of more than 90 million annual units. Global group Reig Jofré billing amounts to more than 100 million euros, employs more than 560 people between Spain and Sweden and exported internationally more than 50% of its turnover.